Clinical and Radiological Features Between Patients with Stable COPD from Plateau and Flatlands: A Comparative Study

References

• Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021 report. Available from: http://www.goldcopd.org/. Accessed January 15, 2021.
   Google Scholar
• Li X, Cao X, Guo M, Xie M, Liu X. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017. BMJ. 2020;368:m234. doi:10.1136/bmj.m234
   PubMed Web of Science ®Google Scholar
• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9
   PubMed Web of Science ®Google Scholar
• Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122. doi:10.1186/1465-9921-11-122
   PubMed Web of Science ®Google Scholar
• Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604. doi:10.1164/rccm.200912-1843CC
   PubMed Web of Science ®Google Scholar
• Siafakas N, Corlateanu A, Fouka E. Phenotyping before starting treatment in COPD? COPD. 2017;14(3):367–374. doi:10.1080/15412555.2017.1303041
   PubMedGoogle Scholar
• Burtscher M. Effects of living at higher altitudes on mortality: a narrative review. Aging Dis. 2013;5(4):274–280. doi:10.14336/AD.2014.0500274
   PubMed Web of Science ®Google Scholar
• Guo Y, Xing Z, Shan G, et al. Prevalence and risk factors for COPD at high altitude: a large cross-sectional survey of subjects living between 2100–4700 m above sea level. Front Med. 2020;7:581763. doi:10.3389/fmed.2020.581763
   Web of Science ®Google Scholar
• Horner A, Soriano JB, Puhan MA, et al. Altitude and COPD prevalence: analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study. Research. 2017;18(1):62. doi:10.1186/s12931-017-0643-5
   Google Scholar
• Brakema EA, Tabyshova A, Kasteleyn MJ, et al. High COPD prevalence at high altitude: does household air pollution play a role? Eur Respir J. 2019;53(2):1801193. doi:10.1183/13993003.01193-2018
   PubMed Web of Science ®Google Scholar
• Olloquequi J, Silva OR. Biomass smoke as a risk factor for chronic obstructive pulmonary disease: effects on innate immunity. Innate Immun. 2016;22(5):373–381. doi:10.1177/1753425916650272
   PubMed Web of Science ®Google Scholar
• Liang Y, Yangzom D, Tsokyi L, et al. Clinical and radiological features of COPD patients living at ≥3000 m above sea level in the Tibet plateau. Int J Chron Obstruct Pulmon Dis. 2021;16:2445–2454. doi:10.2147/copd.S325097
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. doi:10.1136/thx.54.7.581
   PubMed Web of Science ®Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805
   PubMed Web of Science ®Google Scholar
• Wang Z, Gu S, Leader JK, et al. Optimal threshold in CT quantification of emphysema. Eur Radiol. 2013;23(4):975–984. doi:10.1007/s00330-012-2683-z
   PubMed Web of Science ®Google Scholar
• Occhipinti M, Paoletti M, Bartholmai BJ, et al. Spirometric assessment of emphysema presence and severity as measured by quantitative CT and CT-based radiomics in COPD. Respir Res. 2019;20(1):101. doi:10.1186/s12931-019-1049-3
   PubMedGoogle Scholar
• Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697–722. doi:10.1148/radiol.2462070712
   PubMed Web of Science ®Google Scholar
• Smith IE, Jurriaans E, Diederich S, Ali N, Shneerson JM, Flower CD. Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax. 1996;51(9):914–918. doi:10.1136/thx.51.9.914
   PubMed Web of Science ®Google Scholar
• Bhalla M, Turcios N, Aponte V, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology. 1991;179(3):783–788. doi:10.1148/radiology.179.3.2027992
   PubMed Web of Science ®Google Scholar
• Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med. 2012;367(10):913–921. doi:10.1056/NEJMoa1203830
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1376–1395. doi:10.1164/ajrccm.161.4.16141
   PubMedGoogle Scholar
• van Gemert F, Kirenga B, Chavannes N, et al. Prevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional observational study. Lancet Glob Health. 2015;3(1):e44–e51. doi:10.1016/S2214-109X(14)70337-7
   PubMed Web of Science ®Google Scholar
• Salvi SS, Brashier BB, Londhe J, et al. Phenotypic comparison between smoking and non-smoking chronic obstructive pulmonary disease. Respir Res. 2020;21(1):50. doi:10.1186/s12931-020-1310-9
   PubMed Web of Science ®Google Scholar
• Nicolaou L, Checkley W. Differences between cigarette smoking and biomass smoke exposure: an in silico comparative assessment of particulate deposition in the lungs. Environ Res. 2021;197:111116. doi:10.1016/j.envres.2021.111116
   PubMed Web of Science ®Google Scholar
• Kamenar K, Hossen S, Gupte AN, et al. Previous tuberculosis disease as a risk factor for chronic obstructive pulmonary disease: a cross-sectional analysis of multicountry, population-based studies. Thorax. 2021;77(11):1088–1097. doi:10.1136/thoraxjnl-2020-216500
   PubMed Web of Science ®Google Scholar
• Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev. 2018;27(147):170077. doi:10.1183/16000617.0077-2017
   PubMed Web of Science ®Google Scholar
• Mishra VK, Retherford RD, Smith KR. Biomass cooking fuels and prevalence of tuberculosis in India. Int J Infect Dis. 1999;3(3):119–129. doi:10.1016/s1201-9712(99)90032-2
   PubMedGoogle Scholar
• Saito M, Pan WK, Gilman RH, et al. Comparison of altitude effect on Mycobacterium tuberculosis infection between rural and urban communities in Peru. Am J Trop Med Hygiene. 2006;75(1):49–54. doi:10.4269/ajtmh.2006.75.49
   PubMed Web of Science ®Google Scholar
• Meneghini AC, Koenigkam-Santos M, Pereira MC, et al. Biomass smoke COPD has less tomographic abnormalities but worse hypoxemia compared with tobacco COPD. Braz J Med Biol Res. 2019;52(5):e8233. doi:10.1590/1414-431x20198233
   PubMed Web of Science ®Google Scholar
• Camp PG, Ramirez-Venegas A, Sansores RH, et al. COPD phenotypes in biomass smoke- versus tobacco smoke-exposed Mexican women. Eur Respir J. 2014;43(3):725–734. doi:10.1183/09031936.00206112
   PubMed Web of Science ®Google Scholar
• Devaraj A, Wells AU, Meister MG, Corte TJ, Wort SJ, Hansell DM. Detection of pulmonary hypertension with multidetector CT and echocardiography alone and in combination. Radiology. 2010;254(2):609–616. doi:10.1148/radiol.09090548
   PubMed Web of Science ®Google Scholar
• Ng CS, Wells AU, Padley SP. A CT sign of chronic pulmonary arterial hypertension: the ratio of main pulmonary artery to aortic diameter. J Thorac Imaging. 1999;14(4):270–278. doi:10.1097/00005382-199910000-00007
   PubMed Web of Science ®Google Scholar
• Aguirre-Franco C, Torres-Duque CA, Salazar G, Casas A, Jaramillo C, Gonzalez-Garcia M. Prevalence of pulmonary hypertension in COPD patients living at high altitude. Pulmonology. 2022. doi:10.1016/j.pulmoe.2021.12.006
   PubMedGoogle Scholar
• Dunham-Snary KJ, Wu D, Sykes EA, et al. Hypoxic Pulmonary Vasoconstriction: from Molecular Mechanisms to Medicine. Chest. 2017;151(1):181–192. doi:10.1016/j.chest.2016.09.001
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–442. doi:10.1016/s2213-2600(15)00106-x
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398. doi:10.1016/s2213-2600(16)00100-4
   PubMed Web of Science ®Google Scholar
• Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax. 2013;68(12):1105–1112. doi:10.1136/thoraxjnl-2012-203175
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Fabbri LM, Ferguson GT, et al. Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD. Chest. 2017;152(6):1169–1178. doi:10.1016/j.chest.2017.07.007
   PubMed Web of Science ®Google Scholar